Ichnos Glenmark Innovation’s phase 1 study of trispecific antibody shows strong results in myeloma treatment
Ichnos Glenmark Innovation (IGI), a collaboration between Glenmark Pharmaceuticals Limited and Ichnos Sciences Inc., has unveiled promising results from its Phase 1 clinical trial involving the trispecific antibody ISB 2001. The announcement was made ahead of the 66th American Society of Hematology (ASH) Annual Meeting, which is set to take place in December 2024 in […]